Fader, 2018 study with Trastuzumab

Question 1

Study question for Fader 2018?

Answer 1

Trastuzumab targets HER2/neu overexpressed in 30% of USC. So compare carbo/taxol w/ and w/o trastuzumab

Question 2

Study design of Fader 2018

Answer 2

RCT; carbo/taxol 6C +/- trastuzumab (experiment)

Question 3

Inclusion criteria for Fader 2018?

Answer 3

Stage III or IV or recurrent HER2/neu +ve disease; n=61

Question 4

Results of Fader, 2018

Answer 4

PFS - 8 mo vs 12.6 mo (exp) for ALL
Stage III or IV with 1’ tx: 9.3 vs 17.9 mo
Recurrent: 6 vs 9.2 mo (exp)